论文部分内容阅读
目的:观察黄芪颗粒对急性病毒性心肌炎患儿血清中白细胞介素(IL)-17和肿瘤坏死因子(TNF)-α的影响。方法:将82例患儿随机分为2组。常规组采用常规治疗,治疗组在常规组的基础上联合黄芪颗粒治疗。评价2组患儿临床疗效。检测患儿治疗前后血清中IL-17和TNF-α浓度。结果:治疗组临床治愈率为24.32%,总有效率为89.19%,常规组分别为8.57%和71.43%,2组临床治愈率、总有效率分别比较,差异均有显著性意义(P<0.05)。治疗前常规组和治疗组IL-17和TNF-α均明显高于健康组,差异均有非常显著性意义(P<0.01)。治疗后2组分别与治疗前比较,各项指标明显改善,差异均有非常显著性意义(P<0.01);2组治疗后比较,差异有非常显著性意义(P<0.01)。结论:黄芪颗粒可能通过下调急性病毒性心肌炎患儿血清中IL-17和TNF-α浓度,抑制炎症反应,提高急性病毒性心肌炎患儿临床疗效,值得临床推广。
Objective: To observe the effect of Astragalus Granules on the levels of serum interleukin (IL) -17 and tumor necrosis factor (TNF) -α in children with acute viral myocarditis. Methods: 82 cases were randomly divided into two groups. The conventional group was treated with routine treatment, and the treatment group was treated with astragalus membranaceus on the basis of the conventional group. Evaluation of two groups of children with clinical efficacy. Serum levels of IL-17 and TNF-α in children before and after treatment were measured. Results: The clinical cure rate was 24.32% in the treatment group, the total effective rate was 89.19%, the conventional group was 8.57% and 71.43% respectively. The clinical cure rate and total effective rate in the two groups were significantly different (P <0.05 ). Before treatment, the levels of IL-17 and TNF-α in routine group and treatment group were significantly higher than those in healthy group, with significant difference (P <0.01). After treatment, the two groups were compared with before treatment, the indicators were significantly improved, the differences were significant (P <0.01); two groups after treatment, the difference was significant (P <0.01). Conclusion: Astragalus Granules can reduce the serum levels of IL-17 and TNF-α in children with acute viral myocarditis, inhibit the inflammatory reaction and improve the clinical efficacy of children with acute viral myocarditis, which is worthy of clinical promotion.